Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $277.10 | Total: $1,385.50 |
| 1 | 10 | $234.72 | Total: $2,347.20 |
| 1 | 25 | $198.86 | Total: $4,971.50 |
| 1 | 50 | $169.52 | Total: $8,476.00 |
| 1 | 100 | $146.70 | Total: $14,670.01 |
Overview
Cbl-b-IN-3 is a potent proto-oncogene-B (CPL-B) inhibitor of casitas B-series lymphoma (ic50 < 1 nM). Cpl-b, a cyclic E3 ubiquitin protein ligase, is involved in the setting of T lymphocyte activation thresholds. Cpl-b negatively regulates p85 in an independent proteolytic manner, and participates in the recruitment of p85 to CD28 and T cell antigen receptor ? through its E3 ubiquitin ligase activity. Inhibition of PI3K inhibits the enhancement of Cblb- -T cell activation.
Chemical Properties
| Molecular Formula | C30H34F3N5O |
| Molecular Weight | 537.62 |
| CAS Numbers | 2573775-59-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CN1C([C@]2(C[C@@H](C)C2)C3=CC(=CC=C3)N4CC=5C(C4=O)=CC(CN6C[C@@H](C)CCC6)=CC5C(F)(F)F)=NN=C1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Arthur T., et al. Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof. WO2020264398A1.